STOCK TITAN
  1. Home
  2. News
  3. PHIO

Phio Pharmaceuticals Corp - PHIO STOCK NEWS

Welcome to our dedicated news page for Phio Pharmaceuticals (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Phio Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Phio Pharmaceuticals's position in the market.

News
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
Rhea-AI Summary
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the dosing of the first patient in the Phase 1b clinical trial of PH-762, an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells’ ability to kill cancer cells. The trial aims to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762 and assess the tumor response in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
clinical trial
-
News
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
Rhea-AI Summary
Phio Pharmaceuticals Corp. announced new preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The data highlights the benefit of combining their INTASYL compound targeting CTLA-4 with systemic anti-PD-1 antibody therapy. The combination significantly enhanced the efficacy of anti-PD-1 therapy, leading to complete regression of around 40% of treated tumors in a mouse model. The INTASYL compound also improved the efficacy of anti-PD-1 therapy on tumors not directly treated with the compound. Additionally, it increased the percentage of reactive CD8+ T cells while decreasing immunosuppressive macrophages in the tumor micro-environment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.57%
Tags
none
-
News
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Rhea-AI Summary
Phio Pharmaceuticals to present new preclinical data at SITC Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.31%
Tags
conferences
News
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
Rhea-AI Summary
Phio Pharmaceuticals presents preclinical data on INTASYL compound PH-894 at AACR-NCI-EORTC Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
87.05%
Tags
none
-
News
Phio CEO to Speak at Wainwright Conference in New York in September
Rhea-AI Summary
Phio Pharmaceuticals CEO to present at H.C. Wainwright Conference, discussing FDA IND approvals for lead product PH-762 and new leadership team
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
News
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
Rhea-AI Summary
Phio Pharmaceuticals announces first patient dosed in Adoptive Cell Therapy trial for metastatic melanoma and solid tumors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
clinical trial
News
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Phio Pharmaceuticals reports Q2 2023 financial results and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
earnings
-
News
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
offering
-
News
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.15%
Tags
offering
News
Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
clinical trial
Stock PHIO logo
Phio Pharmaceuticals Corp

Nasdaq:PHIO

PHIO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PHIO Stock Data

3.09M
4.55M
0.4%
11.04%
0.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Marlborough

About PHIO

phio pharmaceuticals corp., a biotechnology company, develops immuno-oncology therapeutics in the united states. it offers intasyl therapeutic platform focuses on silencing tumor-induced suppression of the immune system. the company develops ph-762 which targets the checkpoint protein pd-1 on immune cells for used in adoptive cell transfer (act); ph-804 that targets the suppressive immune receptor tigit, which is a checkpoint protein present on t cells and natural killer cells for used in act; and ph-790 which targets pd-l1 protein that keeps immune cells from attacking nonharmful cells in the body. it has collaborations with the gustave roussy and medigene ag, as well as with helmholtz zentrum mã¼nchen. the company was formerly known as rxi pharmaceuticals corporation and changed its name to phio pharmaceuticals corp. in november 2018. phio pharmaceuticals corp. was incorporated in 2011 and is headquartered in marlborough, massachusetts.